Form 4: Corvus Pharmaceuticals Director Receives Stock Options

Director Andrew C. Chan was granted 30,000 stock options in Corvus Pharmaceuticals, Inc. as part of a standard equity incentive.

Summary

• Director Andrew C. Chan acquired 30,000 stock options in Corvus Pharmaceuticals, Inc. (CRVS).
• The options have an exercise price of $16.02 per share.
• The grant date for these options is April 23, 2026.
• The options are set to expire on April 23, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of CRVS common stock.

Future Outlook

The options vest in three equal annual installments starting April 23, 2027, contingent upon the director's continued service with the company.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to incentivize long-term oversight and strategic alignment, particularly for companies in the clinical development stage.

Comparison to Industry Standards

• The three-year vesting schedule is consistent with standard corporate governance practices for board members in the life sciences industry.
• The use of stock options as a primary component of director compensation is typical for mid-cap and small-cap pharmaceutical firms.

Stakeholder Impact

• Minor potential dilution for existing shareholders if options are exercised in the future.

Next Steps

• Vesting of the first tranche of 10,000 options on April 23, 2027.

Key Dates

Keywords

Corvus Pharmaceuticals, CRVS, Form 4, Insider Trading, Stock Options, Director Compensation